More details have emerged on the group of COVID-19 patients who received dexamethasone in the RECOVERY trial. These data, published as a preliminary report in the New England Journal of Medicine (NEJM), suggest that dexamethasone could reduce mortality in cases when infection effects are mainly derived from immunopathological elements in patients requiring mechanical ventilation or…